Jihye Kim, Moon Haeng Hur, Seung Up Kim, Jin-Wook Kim, Dong Hyun Sinn, Hyun Woong Lee, Moon Young Kim, Jae Youn Cheong, Yong Jin Jung, Han Ah Lee, Young-Joo Jin, Jun Sik Yoon, Sung-Jae Park, Chang Hun Lee, In Hee Kim, June Sung Lee, Young Youn Cho, Hyung Joon Kim, Soo Young Park, Yeon Seok Seo, Hyunwoo Oh, Dae Won Jun, Mi Na Kim, Young Chang, Jae Young Jang, Sang Youn Hwang, Yoon Jun Kim
Tenofovir disoproxil fumarate (TDF) is reportedly superior or at least comparable to entecavir (ETV) in preventing hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients; however, it remains controversial. This study aimed to conduct comprehensive comparisons between the two antivirals. CHB patients initially treated with ETV or TDF between 2012 and 2015 at 20 referral centers in Korea were included. The primary outcome was the cumulative incidence of HCC. The secondary outcomes included death or liver transplantation, liver-related outcome, extrahepatic malignancy, development of cirrhosis, decompensation events, complete virologic response (CVR), seroconversion rate, and safety...
May 26, 2023: Cancers